About Guy Webber
I’m a senior DMPK and preclinical development scientist based in Northamptonshire, UK, with more than 30 years in pharma, biotech and contract research. I have guided compounds from discovery through candidate selection and IND/CTA-enabling studies into Phase I.
My teams have provided full DMPK and DDI support to four successful NDAs, including Epidiolex, the first FDA-approved cannabis-derived medicine, where I was part of the GW Pharmaceuticals NDA team.
My focus is applying modern in vitro science to the questions that matter most: early de-risking, regulatory DDI, MIST and hiDILI liability assessment. I have developed and led DMPK groups in both CRO and pharma settings. I speak regularly at scientific meetings and webinars on regulatory DDI, MIST and hiDILI.
Career highlights
| Organisation | Role |
|---|---|
| ICON Clinical Research | Senior Director, Preclinical/Non-clinical Consulting (2022–2025) |
| Evotec | Group Leader, Early DMPK (2020–2021) |
| Covance (now Labcorp) | Commercial and Scientific Manager (2019–2020) |
| Envigo | Scientific Manager, In Vitro and DDI Sciences (2015–2019) |
| GW Pharmaceuticals | ADME and DDI Projects Manager (2014–2015) |
| Quotient Bioresearch (now Pharmaron) | Chief Scientist and Head of In Vitro and DDI Sciences (2008–2014) |
| BioDynamics Research | Head of In Vitro Metabolism (2000–2008) |
| GlaxoSmithKline | Research Scientist (1997–2000) |
Current roles
Alongside DMPK Consulting Services (founded 2021), I am Director of Preclinical Development at Phytanix Bio, Senior Consulting Partner at North Rode Scientific Services and Senior Adviser to DeepCyte Bio.
Education
MSc Medicinal Chemistry and Drug Metabolism and BSc (Hons) Chemistry, Loughborough University.
